Observational studyStem cell research & therapy2025
Intra-ovarian injection of autologous menstrual blood-derived-mesenchymal stromal cells: a safe and promising method to improve pregnancy rate in poor ovarian responders.
Observational study in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Potential and Challenges of Menstrual Blood-derived Mesenchymal Stem Cells/Stromal Cells in Treating Female Infertility: A Recent Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Mesenchymal stem cell-based therapeutic strategies for female infertility: current evidence and emerging targeting approaches.Biotechnology letters · 2026Review
- Mesenchymal stem cell therapy for premature ovarian insufficiency: progress and challenges.Journal of ovarian research · 2026Review
- Review
- The secrets of menstrual blood: emerging frontiers from diagnostic tools to stem cell therapies.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor ovarian response (POR) significantly reduces the success rates of fertility treatments. This study investigates the long-term efficacy and potential complications associated with autologous menstrual blood-derived mesenchymal stromal cells (MenSCs) therapy in improving fertility outcomes for women with POR.
objectiveTo evaluate the long-term efficacy and potential complications associated with MenSC therapy in improving fertility outcomes for women with POR.
methodsThis longitudinal, single-center retrospective observational study included 105 POR patients who received autologous MenSC injections from August 2018 to September 2021. Participants were monitored for at least 3 years, and demographic, menstrual, and fertility data were collected. Potential complications were also assessed during this period. Statistical analyses were performed to determine pregnancy rates and possible complications.
resultsThe average age of participants at the time of injection was 37.91 years. During the follow-up period, 36.19% of women became pregnant, with a live birth rate of 30.48% per treatment cycle. The treatment showed no significant difference in pregnancy rates between women with regular and irregular menstrual cycles. The spontaneous pregnancy rate was also notably higher within the first three months post-injection. No significant complications such as endometriosis, ovarian malignancies, or autoimmune disorders were observed. Only one case of an ovarian cyst, which resolved without intervention, was reported. MenSC treatment did not increase the risk of congenital anomalies or infant mortality.
conclusionIntra-ovarian injection of MenSCs is a safe and promising method for improving pregnancy outcomes in women with POR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.